Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jan;59(1):97–99. doi: 10.1038/bjc.1989.19

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.

A L Harris 1, J Carmichael 1, B M Cantwell 1, M Dowsett 1
PMCID: PMC2246980  PMID: 2527049

Abstract

The endocrine and therapeutic effects of the LHRH agonist Zoladex have been assessed in 28 post-menopausal women with advanced breast cancer. Fourteen had responded to previous hormone therapy and 14 had no previous hormone therapy. There were two partial responses and two patients with stable disease for more than 6 months in the former group, and one partial response and two with stable disease for more than 6 months in the latter group. Toxicity was minimal. All responses occurred in soft tissue. Six out of seven patients who received tamoxifen after progression of disease on Zoladex showed a response. Peripheral oestradiol levels were measured, and they fell after 1 month from 33 pmol l-1 (+/- 20, s.d.) to 22 pmol l-1 (+/- 11, s.d.) (P less than 0.005). Responders and non-responders showed similar changes in oestradiol. Oestrone levels did not change significantly. These results suggest that Zoladex acts indirectly via changes in peripheral hormones, rather than directly on LHRH receptors on the tumour.

Full text

PDF
97

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bezwoda W. R., Mansoor N., Dansey R. Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology. 1987;44(6):345–349. doi: 10.1159/000226509. [DOI] [PubMed] [Google Scholar]
  2. Blankenstein M. A., Henkelman M. S., Klijn J. G. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol. 1985 Dec;21(12):1493–1499. doi: 10.1016/0277-5379(85)90244-5. [DOI] [PubMed] [Google Scholar]
  3. Clayton R. N., Bailey L. C., Cottam J., Arkell D., Perren T. J., Blackledge G. R. A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRH. Clin Endocrinol (Oxf) 1985 Apr;22(4):453–462. doi: 10.1111/j.1365-2265.1985.tb00144.x. [DOI] [PubMed] [Google Scholar]
  4. Dowsett M., Cantwell B., Lal A., Jeffcoate S. L., Harris A. L. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab. 1988 Apr;66(4):672–677. doi: 10.1210/jcem-66-4-672. [DOI] [PubMed] [Google Scholar]
  5. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  6. Eidne K. A., Flanagan C. A., Millar R. P. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science. 1985 Sep 6;229(4717):989–991. doi: 10.1126/science.2992093. [DOI] [PubMed] [Google Scholar]
  7. Foekens J. A., Henkelman M. S., Fukkink J. F., Blankenstein M. A., Klijn J. G. Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. Biochem Biophys Res Commun. 1986 Oct 30;140(2):550–556. doi: 10.1016/0006-291x(86)90767-9. [DOI] [PubMed] [Google Scholar]
  8. Grodin J. M., Siiteri P. K., MacDonald P. C. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973 Feb;36(2):207–214. doi: 10.1210/jcem-36-2-207. [DOI] [PubMed] [Google Scholar]
  9. Harris A. L., Dowsett M., Jeffcoate S. L., Smith I. E. Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol. 1983 Apr;19(4):493–498. doi: 10.1016/0277-5379(83)90112-8. [DOI] [PubMed] [Google Scholar]
  10. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. Br J Cancer. 1983 Oct;48(4):585–594. doi: 10.1038/bjc.1983.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol. 1984 Apr;20(4):463–469. doi: 10.1016/0277-5379(84)90230-x. [DOI] [PubMed] [Google Scholar]
  12. Judd H. L., Judd G. E., Lucas W. E., Yen S. S. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab. 1974 Dec;39(6):1020–1024. doi: 10.1210/jcem-39-6-1020. [DOI] [PubMed] [Google Scholar]
  13. Judd H. L., Shamonki I. M., Frumar A. M., Lagasse L. D. Origin of serum estradiol in postmenopausal women. Obstet Gynecol. 1982 Jun;59(6):680–686. [PubMed] [Google Scholar]
  14. Miller W. R., Scott W. N., Morris R., Fraser H. M., Sharpe R. M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 1985 Jan 17;313(5999):231–233. doi: 10.1038/313231a0. [DOI] [PubMed] [Google Scholar]
  15. Nicholson R. I., Walker K. J., Turkes A., Dyas J., Plowman P. N., Williams M., Blamey R. W. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J Steroid Biochem. 1985 Nov;23(5B):843–847. doi: 10.1016/s0022-4731(85)80025-x. [DOI] [PubMed] [Google Scholar]
  16. Plowman P. N., Nicholson R. I., Walker K. J. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer. 1986 Dec;54(6):903–909. doi: 10.1038/bjc.1986.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Radford J. A., Knight R. K., Rubens R. D. Mitomycin C and vinblastine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol. 1985 Dec;21(12):1475–1477. doi: 10.1016/0277-5379(85)90241-x. [DOI] [PubMed] [Google Scholar]
  18. Wander H. E., Blossey H. C., Nagel G. A. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol. 1986 Nov;22(11):1371–1374. doi: 10.1016/0277-5379(86)90147-1. [DOI] [PubMed] [Google Scholar]
  19. Waxman J. H., Harland S. J., Coombes R. C., Wrigley P. F., Malpas J. S., Powles T., Lister T. A. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol. 1985;15(2):171–173. doi: 10.1007/BF00257531. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES